Tech Company Financing Transactions
Vero Biotech Funding Round
Horizon Technology Finance and Monroe Capital participated in a $65 million venture round for Vero Biotech. The round closed on 2/7/2024.
Transaction Overview
Company Name
Announced On
2/7/2024
Transaction Type
Debt
Amount
$65,000,000
Round
Undisclosed
Investors
Horizon Technology Finance (Dan Devorsetz)
Proceeds Purpose
This funding will support the continued commercial expansion of the Genosyl, as well as other R&D initiatives.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
387 Technology Cir. NW 125
Atlanta, GA 30313
USA
Atlanta, GA 30313
USA
Phone
Website
Email Address
Overview
At VERO Biotech, our mission is to improve the lives of patients by developing innovative technologies for inhaled nitric oxide delivery in the acute care hospital setting and beyond, wherever nitric oxide treatment is needed.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Brent Furse
Chief Financial Officer
Marc Morin
Chief Technical Officer
Eric Finkelman
Vice President
Namita Khanna
Vice President
David Stocker
VP - Customer Service
Michelle Nickoli
VP - Human Resources
Lindsey Peterson
VP - R & D
Jason White
Browse more venture capital transactions:
Prev: 2/7/2024: Rize venture capital transaction
Next: 2/7/2024: Polycam venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC investment data records on this site come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs